Features of the blast phase, such as blast cell morphology and accompanying cytogenetic changes, vary between chronic myeloid leukaemia patients who received tyrosine kinase inhibitor therapy and those treated in the pre-TKI era, research shows.

Continue reading here:
Blast phase characteristics differ in TKI-, non-TKI–treated CML patients

Scroll to Top